Navigation Links
Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
Date:10/23/2007

."

Of the 15 evaluable patients who achieved stable disease or PRs, eight remain on study and are continuing to receive additional cycles of treatment. Of note, four of the patients with measurable tumor shrinkage, including the two patients with PRs, previously failed prior platinum-containing regimens and treatment with doxorubicin HCl liposome injection (Doxil(R)). Of the 2 patients with PRs, one has received eight cycles of treatment and continues on study. The other patient progressed within 60 days of initial response.

Sunesis plans to enroll approximately 55 patients in this clinical trial. Thirty-one patients have been enrolled to date, and Sunesis expects to complete enrollment and present additional data in 2008.

"We are pleased to report SNS-595's early, yet positive, demonstration of clinical activity. We have met the pre-specified criterion to advance this compound to the second stage of our Phase 2 clinical trial, by showing sufficient evidence of anti-tumor activity," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Additionally, the data suggests that SNS-595 may have potentially meaningful activity among platinum-resistant ovarian cancer patients who have also failed treatment with Doxil."

In parallel with the Phase 2 clinical trial, a non-clinical study was conducted to evaluate the activity of SNS-595 against 17 archived ovarian tumor biopsy specimens in the Extreme Drug Resistance (EDR(R)) cell proliferation assay. SNS-595 activity was compared to doxorubicin, etoposide and carboplatin -- agents used commonly in the treatment of ovarian cancer. Results from this study demonstrate that SNS-595 is a potent inhibitor of ovarian tumor cell growth, with activity comparing favorably to these agents. Further, none of the ovarian tumor samples showed any resistance to SNS-595.

These data were presented today during Poster Session A -- Clinical Trials at the AACR-NCI-EORT
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
3. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
4. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
5. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2007 - Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced ... Conference that its interim,analysis of the blinded ... the,Fast-Tracked Phase 3 clinical study of SinuNase(TM), ... in,resolution of one or both of the ...
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
Cached Medicine Technology:Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 2Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 3Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5
(Date:7/11/2014)... Ashburn, Virginia (PRWEB) July 11, 2014 ASHBURN ... 367 took effect, which allows individuals with an intellectual disability ... back of their licenses and ID cards to alert law ... with a condition. The idea was inspired by a ... proactive in protecting her 9 year old autistic son, JP. ...
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Thousands of researchers from more than ... 13-17 to reveal the latest study results, theories ... in dementia science. The Alzheimer’s Association International Conference ... kind. , As part of the Alzheimer’s Association’s ... generating new knowledge about dementia and fostering a ...
(Date:7/10/2014)... City, NY (PRWEB) July 10, 2014 ... life sciences industry, has launched a new website. ... as well as increased access to the firm’s thought ... cbpartners.com provides an ideal platform to showcase our insights, ... access issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
Breaking Medicine News(10 mins):Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... Parents really need to stop their kids from becoming mini-couch ... dont get regular exercise are at risk of chronic ... of their study, researchers from the British Heart Foundation examined ... secondary schools in Leicester. ,They found that half ...
... conducted by a team of researchers led by Dr Peter ... ,As part of the study, researchers analysed schoolchildren who ... ,Researchers asked their parents about their kids fruit ... ,The study found that although there was no connection between ...
... of climbers have collected half a tonne of junk littered ... Monday . ,The garbage was mostly left behind ... kilos of essential items are hauled up the mountain in ... Ken Noguchi told reporters here that the expedition collected garbage ...
... exercise appears to modestly increase levels of high-density ... meta-analysis study in the issue of Archives of ... high-density lipoprotein cholesterol (HDL-C) is an independent risk ... death worldwide, according to background information in the ...
... Substituting soy nuts for other protein sources in a ... women , and also may reduce cholesterol levels in ... in the issue of Archives of Internal Medicine. ... pressure (hypertension) affects approximately 50 million Americans and 1 ...
... studying the addition of sugars to proteins ... system of insects, Karen Palter, researcher of Temple ... better understand neurodegenerative diseases in humans. Currently, her ... exploring the glycosylation process that could eventually play ...
Cached Medicine News:Health News:Apple Juice may Help to Keep Childhood Asthma at Bay 2Health News:Regular Exercise may Slightly Increase HDL Levels 2Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Cryo/Cuffs can be ordered as a single ... tube assembly and insulation disk). The Cooler ...
... designed to comfortably restrict motion of ... motion of the fingers and wrist. ... splint may be trimmed using cast ... gun. One cotton stockinet is included ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: